Drug intelligence / Profile preview

SAB06

Development stage: Preclinical
Lead developer: Santa Ana Bio

Overview

SAB06 is a biological product under development by Santa Ana Bio, Inc. It is being developed primarily for the treatment of Inflammatory Bowel Diseases (IBD) with a focus on addressing inflammation and fibrosis. The exact mechanism of action for SAB06 is currently unknown, and it does not involve a novel mechanism. The drug is in the preclinical stage of development and has not yet been approved by any regulatory authority. No known adverse events or routes of administration have been disclosed at this time.

Beyond the preview

Go deeper on SAB06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAB06.

Explore the full profile